SCHEMBL7963223

SCHEMBL7963223

CCN1CCC(n2c(=O)[nH]c3ccccc32)CC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.77
CYP2C9 P11712 1/20 0.77
CHRM1 P11229 4/20 0.73
OPRM1 P35372 8/20 0.72
OPRK1 P41145 2/20 0.72
OPRL1 P41146 2/20 0.72
KDM4E B2RXH2 1/20 0.69
ALDH1A1 P00352 1/20 0.69
PMP22 Q01453 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69
PLD1 Q13393 2/20 0.66
DRD2 P14416 2/20 0.65
KCNH2 Q12809 1/20 0.65
CHRM2 P08172 2/20 0.64
CHRM4 P08173 2/20 0.64
CHRM3 P20309 2/20 0.64
ADRA1D P25100 2/20 0.64
ADRA1A P35348 2/20 0.64
ADRA1B P35368 2/20 0.64
CHRM5 P08912 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL5772739 0.94 KDM4E (0.79) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL28539041 0.89 CYP2D6 (0.86) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL6404540 0.89 PLD1 (0.81) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL5772590 0.87 CYP2D6 (1.00) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL5984495 0.86 CYP2D6 (0.85) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL23374511 0.85 PLD1 (0.72) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL7586871 0.85 CYP2D6 (0.68) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL5771940 0.85 OPRM1 (0.88) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL6404859 0.85 CHRM1 (0.88) CYP2D6CYP2C9CHRM1OPRM1OPRK1
SCHEMBL7964885 0.85 CHRM1 (1.00) CYP2D6CYP2C9CHRM1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6180649-B1 NERVOUS SYSTEM DISORDERS; ALZHEIMER'S, HUNTINGTON, PARKINSON DISEASE NEROSEARCH A/S (DK) 2001-01-30 US claimed
WO-2021101919-A1 COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN BRISTOL-MYERS SQUIBB COMPANY (US) 2021-05-27 WO disclosed
US-20160143874-A1 HISTONE DEACETYLASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. 2016-05-26 US disclosed
US-8754237-B2 Bifunctional histone deacetylase inhibitors PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-06-17 US disclosed
US-20130018103-A1 BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-01-17 US disclosed
US-8304451-B2 Histone deacetylase and tubulin deacetylase inhibitors PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-11-06 US disclosed
US-7994325-B2 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide MERCK SHARP & DOHME CORP. (US) 2011-08-09 US disclosed
US-20090209590-A1 Histone Deacetylase and Tubulin Deacetylase Inhibitors PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-08-20 US disclosed
US-20080261972-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-10-23 US disclosed
US-20080103178-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives MSD K.K. (JP) 2008-05-01 US disclosed
US-7300947-B2 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-11-27 US disclosed
US-20070015792-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives MSD K.K. (JP) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018103-A1 BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC2 CYP2D6 4357/4885CYP2C9 4130/4885CHRM1 4861/4885
US-20070015792-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives OPRL1, OPRK1, GPR119 CYP2D6 1074/4885CYP2C9 4414/4885CHRM1 59/4885
US-20160143874-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC7 CYP2D6 2697/4885CYP2C9 2157/4885CHRM1 4350/4885
US-20090209590-A1 Histone Deacetylase and Tubulin Deacetylase Inhibitors HDAC6, HDAC1, HDAC5 CYP2D6 3555/4885CYP2C9 4505/4885CHRM1 4451/4885
US-20080261972-A1 Cgrp Receptor Antagonists BDKRB1, CALCRL, NPY1R CYP2D6 2151/4885CYP2C9 1883/4885CHRM1 243/4885
US-20080103178-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives OPRL1, OPRK1, GPR119 CYP2D6 1074/4885CYP2C9 4414/4885CHRM1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.